Last reviewed · How we verify
Bepreve 1.5% Ophthalmic Solution — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Bepreve 1.5% Ophthalmic Solution (Bepreve 1.5% Ophthalmic Solution) — Minnesota Eye Consultants, P.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bepreve 1.5% Ophthalmic Solution TARGET | Bepreve 1.5% Ophthalmic Solution | Minnesota Eye Consultants, P.A. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bepreve 1.5% Ophthalmic Solution CI watch — RSS
- Bepreve 1.5% Ophthalmic Solution CI watch — Atom
- Bepreve 1.5% Ophthalmic Solution CI watch — JSON
- Bepreve 1.5% Ophthalmic Solution alone — RSS
Cite this brief
Drug Landscape (2026). Bepreve 1.5% Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/bepreve-1-5-ophthalmic-solution. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab